T. Rowe Price Associates
CLPT icon

T. Rowe Price Associates’s ClearPoint Neuro CLPT Stock Holding History

T. Rowe Price Associates’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$270K Buy
29,619
+2,828
+11% +$35.7K ﹤0.01% 2734
2025
Q4 		$367K Buy
26,791
+1,204
+5% +$22.3K ﹤0.01% 2537
2025
Q3 		$558K Buy
25,587
+1,132
+5% +$13.3K ﹤0.01% 2320
2025
Q2 		$292K Buy
24,455
+10,955
+81% +$138K ﹤0.01% 2544
2025
Q1 		$161K Sell
13,500
-4,200
-24% -$65.3K ﹤0.01% 2713
2024
Q4 		$273K Hold
17,700
– – ﹤0.01% 2547
2024
Q3 		$199K Hold
17,700
– – ﹤0.01% 2658
2024
Q2 		$96K Sell
17,700
-7,167
-29% -$41.5K ﹤0.01% 2765
2024
Q1 		$170K Buy
24,867
+1,813
+8% +$12.7K ﹤0.01% 2665
2023
Q4 		$157K Buy
23,054
+688
+3% +$3.89K ﹤0.01% 2613
2023
Q3 		$113K Hold
22,366
– – ﹤0.01% 2636
2023
Q2 		$162K Buy
22,366
+4,666
+26% +$39.7K ﹤0.01% 2591
2023
Q1 		$150K Buy
17,700
+3,700
+26% +$32.4K ﹤0.01% 2593
2022
Q4 		$119K Buy
+14,000
New +$133K ﹤0.01% 2680
2022
Q2 		– Sell
-10,192
Closed -$106K – 2970
2022
Q1 		$106K Buy
+10,192
New +$92.8K ﹤0.01% 2834

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

T. Rowe Price Associates's CLPT Position: Q1 2026 in Review

T. Rowe Price Associates increased its ClearPoint Neuro (CLPT) stake by 11% in Q1 2026, buying an estimated $35.7K and bringing the position to 29,619 shares worth $270K. The position accounts for ﹤0.01% of the portfolio, ranked #2734.

T. Rowe Price Associates first reported a position in CLPT in Q1 2022 and has held it in 15 quarters since. The position peaked at $558K in Q3 2025. 118 funds tracked by Wall St. Rank hold CLPT as of Q1 2026.

  • T. Rowe Price Associates held 29,619 shares of ClearPoint Neuro worth $270K as of Q1 2026.
  • T. Rowe Price Associates bought 2,828 ClearPoint Neuro shares in Q1 2026, an estimated $35.7K.
  • ClearPoint Neuro made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2734 holding.
  • T. Rowe Price Associates first reported a position in ClearPoint Neuro in Q1 2022 and has held it in 15 quarters since.
  • T. Rowe Price Associates's ClearPoint Neuro position peaked at $558K in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.